Germany, Along with France, Italy and the Netherlands, has signed a contract with Astrazeneca to purchase at least 300 million novel Coronavirus vaccines in advance, the Federal Health Ministry said Wednesday.
In the best case scenario, the Novel Coronavirus vaccine could be completed by the end of this year, the Federal Ministry of Health of Germany expects.

Astrazeneca, headquartered in London, Is a global biopharmaceutical company.
Germany’s Federal Health Ministry confirmed the news the same day, according to German TV 1 and frankfurter Allgemeine Zeitung.

The vaccine ordered by the four countries is AZD1222, which is under development at Oxford University and is produced under licence by Astrazeneca.
The vaccine is currently being tested on a large scale.
German media reported that the above-mentioned four countries have signed orders with Astrazeneca for no less than 300 million doses of vaccines, with a maximum of 400 million doses.
Although the four countries are Germany, France, Italy and the Netherlands, the vaccine will be available to all EU members and is expected to be distributed according to population size.

Astrazeneca has recently reached similar agreements with the UK and the US respectively, according to The German Business Weekly.

A German TV, citing the German federal health minister jens pan said, many countries in the world has to ensure that their vaccine supply, however, Europe also didn’t do that, “by the rapidly coordinated action of several eu member states, eu citizens to all of us to benefit in the outbreak of the crisis”.

Germany’s Federal Health Ministry said today that the four countries are holding talks with potential vaccine makers to sign a deal to ensure production capacity so that vaccines can be shipped to the European Union in large quantities.
In addition, the video conference of eu Health ministers held on December 12 also agreed that the “vaccine Alliance” will carry out action in coordination with the European Commission.

The EU has recently invested heavily in speeding up vaccine development and ensuring supplies.
On November 11th the European Investment Bank (EIB), the EU’s multilateral lending arm, announced a €100m investment in BioNTech, a vaccine company based in Mainz, Germany, to boost its vaccine research and production.
According to German media, the European Commission wants to ensure that sufficient quantities of vaccines can be obtained quickly for EU citizens by signing pre-purchase agreements.